|Continuum Health Partners: Beth Israel • Roosevelt Hospital and St. Luke's Hospital • Long Island College Hospital • New York Eye and Ear Infirmary|
|Home | Find A Doctor | Contact Us|
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of
The main purpose of this study is to determine whether the addition of VELCADE to a commonly used drug combination for subjects with diffuse large B-Cell lymphoma called RCHOP (ritxuximab, cyclophosphamide, doxorubicin, vincristine and prednisone) benefits subjects with non-GCB diffuse large B-cell lymphoma and whether this combination can be given safely. RCHOP is standard of care for this type of cancer.
Another purpose of this study is to look for disease markers. These disease markers, called “biomarkers,” in your blood and tumor, are special chemical characteristics that are different between subjects that respond to treatment and those that do not. These disease markers will be examined to see if they are turned on or off before treatment.
Please call for more informations
Copyright © 2008